Rothschild & Co Redburn initiated coverage of Certara (CERT) with a Buy rating and $10 price target The firm views Certara as the leader in biosimulation, which it says can aid the discovery of potential drug targets and reduce the need for early stage clinical work. Certara needs to increase penetration into discovery and preclinical phases, and it acquisition of Chemaxon boosts its presence in these areas, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERT:
- Certara initiated with a Market Perform at BMO Capital
- Certara’s Earnings Call: Mixed Sentiment Amid Growth
- Certara price target lowered to $12 from $13 at Baird
- Certara price target lowered to $14 from $16 at Barclays
- Certara’s Mixed Performance: Strong Profitability Amidst Service Booking Challenges Leads to Hold Rating